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Many drugs and chemicals found in the environment
are either detoxified by N-acetyltransferase 1 (NAT1, EC
2.3.1.5) and eliminated from the body or bioactivated to
metabolites that have the potential to cause toxicity
and/or cancer. NAT1 activity in the body is regulated by
genetic polymorphisms as well as environmental factors
such as substrate-dependent down-regulation and oxi-
dative stress. Here we report the molecular mechanism
for the low protein expression from mutant NAT1 alleles
that gives rise to the slow acetylator phenotype and
show that a similar process accounts for enzyme down-
regulation by NAT1 substrates. NAT1 allozymes NAT1
14, NAT1 15, NAT1 17, and NAT1 22 are devoid of enzyme
activity and have short intracellular half-lives (4 h)
compared with wild-type NAT1 4 and the active alloz-
yme NAT1 24. The inactive allozymes are unable to be
acetylated by cofactor, resulting in ubiquitination and
rapid degradation by the 26 S proteasome. This was
confirmed by site-directed mutagenesis of the active site
cysteine 68. The NAT1 substrate p-aminobenzoic acid
induced ubiquitination of the usually stable NAT1 4,
leading to its rapid degradation. From this study, we
conclude that NAT1 exists in the cell in either a stable
acetylated state or an unstable non-acetylated state and
that mutations in the NAT1 gene that prevent protein
acetylation produce a slow acetylator phenotype.
Human arylamine N-acetyltransferase 1 (NAT1)1 (EC
2.3.1.5) is a ubiquitous enzyme that catalyzes the N-acetyla-
tion of many arylamine and hydrazine xenobiotics. It also
appears to be important in the catabolism of folic acid, where
it acetylates p-aminobenzoylglutamate following cleavage of
the folate molecule (1, 2). The gene that encodes NAT1 is
located at 8p21–22 and exhibits genetic as well as functional
polymorphisms (reviewed in Refs. 3 and 4). Numerous NAT1
alleles have been identified but only a small number result in
altered activity in vivo (5, 6). Recently, Fretland et al. (7)
showed that the NAT1 allozymes that have reduced catalytic
activity (NAT1*14, NAT1*15, NAT1*17, and NAT1*22) com-
pared with wild-type (NAT1*4) are expressed at barely de-
tectable levels in yeast. Because the rate of gene transcrip-
tion did not appear to differ between alleles, they concluded
that a decrease in protein translation and/or protein turnover
was responsible for the very low levels of expression. Inter-
estingly, NAT1-specific substrates such as p-aminobenzoic
acid (PABA) and p-aminosalicylic acid down-regulate enzyme
activity by a mechanism that leads to a decrease in NAT1
protein (8). Again, the loss of protein appeared to occur at a
post-transcriptional level because the drugs did not affect
NAT1 mRNA levels. More recently, NAT1 activity has been
shown to be affected by oxidative stress such as exposure to
hydrogen peroxide or S-nitrosothiols (9, 10). Despite these
observations indicating that NAT1 is regulated at both an
environmental and a genetic level, the molecular mecha-
nisms responsible are poorly understood.
The acetyl-coenzyme A (acetyl-CoA)-dependent acetylation
reaction catalyzed by NAT1 proceeds via a classical ping-pong
bi bi mechanism (11, 12). Initially, the active site cysteine (Cys
68 for human NAT1) of the enzyme accepts an acetyl group
from acetyl-CoA, forming a thiol ester. The second step involves
the binding of substrate to the acetylated enzyme, transfer of
the acetyl group to the substrate, and release of the acetylated
product. The initial acetylation of NAT1 can proceed independ-
ent of the presence of substrate (13). Turnover of acetylated
enzyme in the absence of substrate is relatively slow, probably
because of the exclusion of water from the active site, which is
buried below the surface of the protein (14). However, turnover
is increased in the presence of substrate, suggesting that a
change in equilibrium from an acetylated to a non-acetylated
form may occur.
We hypothesized that NAT1 exists in the cell in either a
stable acetylated state or an unstable non-acetylated state.
Thus, substrates induce down-regulation by shifting the equi-
librium of the protein toward the non-acetylated state. This
mechanism could also explain the apparent instability of the
allozymes expressed from alleles that give rise to the slow
acetylator phenotype if these proteins exist predominantly in
the non-acetylated state. To investigate this, we examined the
half-life of a number of NAT1 allozymes previously reported to
have little or no activity and compared these to the wild-type
NAT1 4. Here we report that the mutant allozymes were not
acetylated by acetyl-CoA. Moreover, these proteins were rap-
idly ubiquitinated in cultured cells. We also show that the
NAT1 substrate PABA can induce ubiquitination of NAT1 4,
leading to its degradation. We conclude that the acetylation
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status of the active site cysteine determines the stability of the
NAT1 protein in vivo and propose that this is the molecular
mechanism responsible for the slow acetylator phenotype of the
alleles investigated in this study. In addition, substrate-de-
pendent down-regulation of human NAT1 occurs because of
enzyme deacetylation and subsequent degradation by the ubiq-
uitin/26 S proteasome pathway.
EXPERIMENTAL PROCEDURES
Cell Culture—HT-29 cells (human colon adenocarcinoma) were
maintained in Dulbecco’s modified Eagle’s medium supplemented with
5% fetal bovine serum, gentamicin (50 g/ml), and benzylpenicillin (80
g/ml). Cultures were incubated at 37 °C in a humidified 5% CO2
atmosphere.
Isolation of PBMC, Total RNA Extraction, and NAT1 Genotyping of
cDNA—Human peripheral blood mononuclear cells (PBMC) were iso-
lated from whole blood using Ficoll-Paque as described previously (6).
Total RNA was extracted from PBMC using a High Pure RNA isolation
kit (Roche Applied Science) and reverse transcribed using avian myelo-
blastosis virus-reverse transcriptase and oligo(dT)15 (Promega). The
NAT1 open reading frame was amplified from cDNA using NAT1-
specific primers and genotyped for NAT1*14 and NAT1*17 as described
previously (6).
Cloning of NAT1 Alleles—The protein coding regions of NAT1*14
and NAT1*17 were amplified by PCR from DNA of heterozygous indi-
viduals using forward primer 5-CCTTGCTTGGATCCTCATGGACAT-
TGAAGC-3 (BamHI) and reverse primer 5-ACTCCGAATTCTAAAT-
AGTAAAA-3 (EcoRI) and cloned into the mammalian expression vector
pEF1/His (Invitrogen). The protein coding regions of NAT1*22 and
NAT1*24 were amplified from plasmids generously provided by Dr. H.
Lin (University of California) using the above primers and cloned into
pEF1/His. Plasmid containing wild-type NAT1 (pEF1/His-NAT1*4) was
kindly provided by Prof. E. Sim (University of Oxford). The NAT1-C68Y
construct was prepared by amplifying the open reading frame of
NAT1*4 as two fragments using the above forward primer and reverse
primer 5-ATGATTGACCTGGAGGTACCATCCAC-3 (KpnI) and for-
ward primer 5-GTGGATGGTACCTCCAGGTC-3 (KpnI) and the above
reverse primer. The PCR fragments were digested with KpnI, ligated
together, amplified by PCR with the primers used to amplify NAT1*14,
and cloned into the BamHI and EcoRI sites of pEF1/His vector.
NAT1*4, NAT1*14, NAT1*17, NAT1*22, NAT1*24, and NAT1-C68Y
were amplified by PCR from the pEF1/His constructs using forward
primer 5-TCCGGAATTCAATGGACATTGAAGC-3 (EcoRI) and re-
verse primer 5-CGCGGATCCTAAATAGTAAAAAATC-3 (BamHI) and
cloned into the mammalian expression vector p3XFLAG-CMV-7.1
(Sigma). The truncated variant NAT1*15 was prepared by PCR as
above using pEF1/His-NAT1*4 as template and reverse primer 5-
CGCGGATCCTAGTATTTGCTGTC-3 (BamHI). Constructs were veri-
fied by DNA sequencing.
Determination of Intracellular NAT1 Half-life—HT-29 cells were
seeded at a density of 2  105 cells/well (24-well plate) and incubated
overnight at 37 °C. Cells were transfected in the absence of fetal bovine
serum with 1 g of plasmid DNA using LipofectAMINE 2000 (Invitro-
gen) according to the manufacturer’s instructions. After a 4-h incuba-
tion at 37 °C, the culture medium was aspirated and replaced with 1
ml/well fresh Dulbecco’s modified Eagle’s medium supplemented with
5% fetal bovine serum and the cells incubated for a further 20 h at
37 °C. Cells were then treated with cycloheximide (10 g/ml) and har-
vested at times 0, 4, and 8 h post-treatment. Cells were washed twice
with 1 ml of PBS, resuspended in 0.8 ml of 20 mM Tris/1 mM EDTA
buffer (pH 7.4) containing 1 mM dithiothreitol, and disrupted on ice
using a cell sonicator (Branson Sonifier B250; duty cycle 100%, out-
put  5; 3  5 s bursts). Cell lysates were then centrifuged for 3 min at
16,000  g (4 °C) and the supernatant retained for Western blot and
assay of NAT1 activity. Protein concentration was determined by the
method of Bradford (15).
NAT1 Activity Assay—NAT1 activities were quantified by HPLC as
described previously using the NAT1-selective substrate PABA (8).
Western Blot Analysis—Cell lysates were electrophoresed on 12%
SDS-PAGE, transferred to nitrocellulose membranes, and immuno-
blotted using a polyclonal NAT1-specific antibody (kindly provided by
Prof. E. Sim, University of Oxford) as described previously (6) or an
anti-FLAG-M2 HRP antibody (A 8592; Sigma) according to the manu-
facturer’s instructions. NAT1 was visualized using Supersignal West
Pico chemiluminescent substrate (Pierce). Protein content was esti-
mated from Western blots by densitometry using ImageQuant Ver. 1.1
(Amersham Biosciences).
Synthesis of [3H]Acetyl-CoA—Coenzyme A (5 mg) was dissolved in
0.5 ml of ammonium hydroxide (100 mM). On ice, [3H]acetic anhydride
(18.5 GBq/mmol; Amersham Biosciences) was added dropwise with
mixing until the reaction was complete, as assessed by thiol assay using
3-carboxy-4-nitrophenyl disulfide (Sigma). The reaction mixture was
purified on a Sep-Pak C18 cartridge (Waters Corp.) and eluted in 0.5 ml
of methanol. The methanol was evaporated at 37 °C under a gentle
stream of N2 and the [
3H]acetyl-CoA residue reconstituted in 0.5 ml of
water. Radiochemical purity assessed by HPLC was 85%, and there
was a single major peak that co-chromatographed with authentic
acetyl-CoA. The major contaminant was acetic acid.
Expression and Purification of Recombinant NAT1 in Escherichia
coli—The open reading frame of NAT1*4, NAT1*24, the slow acetylator
alleles NAT1*14, NAT1*15, NAT1*17, and NAT1*22 and the inactive
NAT1-C68Y were cloned into the bacterial expression vector pGEX-
6P-2 and introduced into the E. coli strain BL21-CodonPlus(DE3)-RP
(Stratagene) by electroporation. Cultures (4 liters of Luria Bertani
containing 100 g/ml chloramphenicol, 50 g/ml tetracycline, and 100
g/ml ampicillin) were grown at 37 °C to an optical density of 0.8 and
then induced with 0.5 mM isopropyl--D-thiogalactopyranoside for 4 h at
room temperature. Bacteria were harvested (4000  g, 10 min, 4 °C)
and the pellets resuspended in 40 ml of lysis buffer (50 mM Tris, 1 mM
EDTA, 0.5 M NaCl at pH 8.0 containing 1 mM dithiothreitol, 1 mM
phenylmethylsulfonyl fluoride, and 0.1 mg/ml DNase I) and lysed using
a French press. The cell lysates were centrifuged at 15 000  g for 30
min at 4 °C and the soluble fraction collected. The GST fusion proteins
were purified using glutathione-agarose beads (G 4510; Sigma) and the
relative amounts of protein estimated by SDS-PAGE and Coomassie
Blue staining.
NAT1 Acetylation Assay—Recombinant GSTNAT1 fusion proteins
(10 g) bound to GSH-agarose beads (Sigma) were incubated with 6.7
M [3H] acetyl-CoA (specific activity  9.25 GBq/mmol) in PBS at 37 °C
for 2 h. The beads were recovered by filtration on 0.45 m nitrocellulose
membranes (Millipore), washed twice with 5 ml of ice-cold PBS, and
radioactivity determined by liquid scintillation spectroscopy. GST
bound to GSH-agarose beads was included to measure nonspecific bind-
ing. Specific binding was calculated by subtracting nonspecific binding
from total binding.
MG132 Treatment and Immunoprecipitation—HT-29 cells were
seeded at a density of 1 106 cells/well (6-well plate) and co-transfected
with 1 g of pFLAG-NAT1 plasmid and 1 g of pcDNA-HA-ubiquitin
plasmid using LipofectAMINE 2000. After overnight incubation at
37 °C, cells were treated with MG132 (20 M, Calbiochem) or vehicle
(Me2SO) for 8 h and then washed twice with 1 ml of PBS and harvested
by scraping into 0.8 ml of 20 mM Tris/1 mM EDTA buffer (pH 7.4)
containing 1 mM dithiothreitol and protease inhibitor mixture (P 8340;
Sigma). Cells were disrupted on ice by sonication and the supernatants
cleared by centrifugation for 3 min at 16,000  g (4 °C). Anti-FLAG-M2
monoclonal antibody (10 g, F 3165; Sigma) was added, and the super-
natants were rotated at 4 °C for 2 h. Protein G-Sepharose 4B (P 3296;
Sigma) was then added and the lysates incubated for a further 1 h at
4 °C. Immunoprecipitates were collected by centrifugation and the
beads washed three times with PBS. The recovered proteins were
separated on 12% SDS-polyacrylamide gels and immunoblotted using
either anti-FLAG-M2 HRP antibody (Sigma) or anti-HA antibody (H
6908; Sigma) according to the manufacturer’s instructions.
RESULTS
NAT1 Protein levels Are Diminished in PBMC from Slow
Acetylator Individuals—Previously, we and others have shown
that individuals heterozygous for either the NAT1*14B or
NAT1*17 slow acetylator alleles had approximately half the
NAT1 activity of individuals who were homozygous wild-type
(NAT1*4) (5). Here, we show by Western blot that PBMC
lysates from individuals heterozygous for either NAT1*14B or
NAT1*17 have lower levels of immunodetectable NAT1 protein
compared with individuals who are homozygous wild-type (Fig.
1A). Moreover, the lower protein levels correlated with a lower
enzyme activity (Fig. 1B), suggesting that the slow acetylator
phenotype results from a reduction in the amount of NAT1. To
determine whether the NAT1*14B and NAT1*17 alleles were
expressed in vivo, cDNA isolated from PBMC obtained from
homozygous and heterozygous individuals was genotyped as
described previously (6). Genotyping showed the presence of
both variant forms of mRNA, indicating that each variant
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allele was expressed in vivo (Fig. 1C).
Expression and Activity of NAT1 Proteins in HT-29 Cells—To
determine protein expression and activity of the variant NAT1
proteins, each allele in the pEF1/His vector was transiently
transfected into the human colon carcinoma cell line, HT-29.
Western blots using a NAT1-specific antibody (Fig. 2A) showed
that His-tagged wild-type NAT1, as well as all of the variant
His-NAT1 proteins (36 kDa), were expressed at levels greater
than endogenous NAT1 (33 kDa). Cells expressing the slow
acetylator His-NAT1 proteins had NAT1 activities that were
not significantly different (p0.05) from the endogenous NAT1
activity of HT-29 cells (5.7  0.1 nmol/min/mg protein), indi-
cating that these variant proteins are catalytically inactive, at
least when PABA is used as substrate (Fig. 2B). Cells express-
ing His-NAT1 4 and His-NAT1 24 had enzymatic activities of
122  1.2 and 130  2.3 nmol/min/mg protein, respectively,
which was more than 20-fold higher than the endogenous ac-
tivity of HT-29 cells.
Stability of NAT1 Proteins in HT-29 Cells—To determine the
stability of the different NAT1 allozymes in vivo, HT-29 cells
were transiently transfected with the various pEF1/His-NAT1
constructs, treated with cycloheximide for up to 8 h, and ana-
lyzed by Western blotting using a NAT1-specific antibody (Fig.
3A). The His-tagged NAT1 proteins were 3 kDa larger than
endogenous NAT1, so the endogenous protein did not interfere
with the protein stability measurements. Endogenous NAT1 4,
His-NAT1 4, and the rapid acetylator protein His-NAT1 24 had
similar stabilities with no noticeable degradation occurring
over the 8-h time period of the experiment (Fig. 3B). In fact, no
significant degradation of His-NAT1 4 occurred over a 24-h
time period of cycloheximide treatment, indicating that the
half-life of the wild-type protein is in excess of 24 h (data not
shown). These results show that the active allozymes were
stable in vivo and that the His tag did not decrease protein
stability. By contrast, all the slow acetylator (inactive) proteins
were considerably less stable, having half-lives of between 2
and 4 h (Fig. 3B). The truncated slow acetylator protein NAT1
15 lacks the epitope for the NAT1-specific antibody used in
these studies, so it was cloned into an N-terminal FLAG-tag
vector so that its half-life could be determined using a FLAG-
specific antibody. To ensure the FLAG tag did not affect protein
stability, FLAG-NAT1*4 and FLAG-NAT1*17 also were con-
structed for comparison (Fig. 3A, lower panels). The half-lives
of FLAG-NAT1 4 and FLAG-NAT1 17 were similar to their
His-tagged counterparts, indicating that the tag had no appre-
ciable effect on protein stability (Fig. 3B). The half-life of
FLAG-NAT1 15 was less than 4 h (Fig. 3B), which was similar
to that observed for the other slow acetylator NAT1 proteins.
The results of the FLAG-tag experiments also show that the
loss of NAT1 protein observed using the NAT1-specific anti-
body raised against the last 11 amino acids of NAT1 (16) was
not because of loss of the epitope because FLAG-NAT1 17
(N-terminal tag) and His-NAT1 17 both had similarly short
half-lives compared with wild-type.
FIG. 1. NAT1 expression in PBMC from individuals with dif-
ferent NAT1 genotypes. A, Western blot analysis of NAT1 from two
wild-type homozygotes (NAT1*4/NAT1*4) and two heterozygotes
(NAT1*17 and NAT1*14B) showing a decrease in immunodetectable
protein in the heterozygotes. B, enzymatic activity in lysates prepared
from PBMC obtained from the same individuals shown in panel A. C,
genotyping of mRNA extracted from PBMC obtained from a NAT1*4/
NAT1*17 heterozygote (lane 1), a NAT1*4/NAT1*14B heterozygote
(lane 2), and a NAT1*4 homozygote (lane 3). The results show the
presence of both RNA species in the two heterozygote individuals.
FIG. 2. Expression of His-tagged NAT1 proteins in HT-29 cells.
A, HT-29 cells were transiently transfected with each expression vector
or empty vector (control), and protein levels were determined by West-
ern blot 24 h later. Endogenous NAT1 (33 kDa) is shown by the lower
band. The tagged proteins chromatographed with a molecular mass of
36 kDa and were expressed at levels much greater than the endogenous
protein. B, NAT1 activity in cell lysates for each NAT1 protein was
determined using PABA as substrate. Control cells were transfected
with empty vector. Data are mean  S.E., n  3. * indicates activities
significantly greater than control samples (p 0.05), by one-way anal-
ysis of variance.
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Acetylation Capacity of NAT1 Allozymes—To determine
whether the inactive NAT1 proteins produced by the slow
acetylator alleles were acetylated by acetyl-CoA, GSTNAT1
fusion proteins were incubated with [3H]acetyl-CoA, and the
radioactivity associated with the proteins was determined. The
active allozymes GSTNAT1 4 and GSTNAT1 24 bound 100
pmol [3H]/nmol protein, whereas all the inactive proteins
bound less than 10% of that seen with the wild-type enzyme
(Fig. 4). The lack of binding was not because of a lack of protein
expression, determined by SDS-PAGE analysis (Fig. 4). Taken
together with the protein stability data above, these results
suggest that NAT1 in the non-acetylated state is rapidly de-
graded in the cell.
Stability of NAT1-C68Y Mutant in HT-29 Cells—To further
investigate the effect of acetylation on NAT1 stability, the
active site cysteine 68 was mutated to a tyrosine to prevent
formation of a thiol ester with acetyl-CoA. This construct
(pEF1/His-NAT1-C68Y) was transfected into HT-29 cells, and
stability was determined using cycloheximide treatment. As
expected, the expressed protein did not acetylate PABA (data
not shown), and when expressed as a GST fusion it did not bind
[3H]acetyl-CoA (Fig. 5A). The level of expression and stability
of His-NAT1-C68Y was similar to that observed for the other
inactive His-NAT1 proteins (Fig. 5, B and C). These results
further support the postulation that the non-acetylated form of
NAT1 is susceptible to rapid degradation in the cell.
Role of the Ubiquitin/26 S Proteasome Pathway in NAT1
Degradation—To determine whether the ubiquitin/26 S protea-
some pathway was involved in the rapid degradation of the
slow acetylator (inactive) NAT1 proteins, the effect of the 26 S
proteasome-specific inhibitor MG132 on the intracellular half-
life of the unstable FLAG-NAT1 17 was investigated. HT-29
cells were transiently transfected with pFLAG-NAT1*17 and
treated with cycloheximide for up to 8 h. In the absence of
MG132, FLAG-NAT1 17 was rapidly degraded (Fig. 6A, left
panel). However, when MG132 (20 M) was added concurrently
with the cycloheximide, the stability of the variant protein
increased significantly with little protein loss occurring over
the 8-h time period of the experiment (Fig. 6A, right panel).
Furthermore, when the experiment was conducted in the ab-
sence of cycloheximide, treatment with MG132 (20 M) for 8 h
resulted in the appearance of higher molecular mass bands,
consistent with ubiquitination of FLAG-NAT1 17 (Fig. 6B).
Higher molecular mass bands also were observed for the other
inactive NAT1 variant proteins but less so for the active vari-
ant protein FLAG-NAT1 24 and the wild-type protein FLAG-
NAT1 4 (Fig. 6B). We next co-expressed each of the FLAG-
tagged allozymes and FLAG-NAT1-C68Y with a HA-tagged
ubiquitin construct to identify ubiquitination of the NAT1 pro-
teins. Following treatment with MG132 and immunoprecipita-
tion with anti-FLAG antibody, Western blotting with anti-HA
antibody showed specific polyubiquitination of the unstable
NAT1 proteins (Fig. 6C), whereas the stable NAT1 24 and
NAT1 4 proteins were polyubiquitinated to a much lesser ex-
tent. Moreover, when cells expressing FLAG-NAT1 4 and HA-
ubiquitin were treated with PABA, significantly more polyu-
biquitination of the immunoprecipitated protein was evident
(Fig. 6D). Taken together, these results show that the unstable
NAT1 allozymes and the non-acetylated stable NAT1 protein
are targeted to the 26 S proteasome pathway by
polyubiquitination.
FIG. 3. Stability of NAT1 proteins in HT-29 cells. A, HT-29 cells
were transiently transfected with 1 g of plasmid DNA (pEF-NAT1*4,
pEF-NAT1*14, pEF-NAT1*17, pEF-NAT1*22, pEF-NAT1*24, or empty
vector), incubated for 24 h, and treated with cycloheximide (10 g/ml).
Cell lysates were prepared at 0, 4, and 8 h for Western blotting. A
NAT1-specific antibody that identifies the last 11 amino acids was used
for the His-tagged proteins. Because NAT1 15 lacks the epitope, this
allele was FLAG-tagged and a FLAG antibody was used for detection
(lowest panel). NAT1 4 and NAT1 17 also were FLAG-tagged as controls
to ensure the tag did not affect stability. B, densitometry scanning was
used to quantify the amount of NAT1 protein at each time point.
Density was normalized to t  0.
FIG. 4. Acetylation capacity of GSTNAT1 fusion proteins.
GSTNAT1 proteins were incubated with [3H]acetyl-CoA and radioac-
tivity associated with the proteins quantified by liquid scintillation
counting. Specific binding was calculated by subtracting nonspecific
binding (GST-bound beads) from total binding. Data are presented as
mean  S.E., n  3. * indicates significantly different (p 0.05) from
NAT1 4. Shown above the graph is an SDS-PAGE gel stained with
Coomassie Blue showing the presence of each expressed protein. NAT1
15 chromatographed at a lower molecular mass compared with the
other proteins and has been digitally shifted for clarity.
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DISCUSSION
Point mutations in the NAT1 locus result in a slow acetylator
phenotype that is observed in 5% of Caucasians and up to
25% in a Lebanese population (6, 17–19). Numerous genotypes
have been reported, but those mutations that affect activity
have only recently been described (6, 7, 19). Expression of 13
common and rare alleles in yeast by Fretland et al. (7) reveals
two possible causes for the slow acetylator phenotype in hu-
mans. First, they observed negligible expression of some alleles
and suggested translational efficiency may be important. Sec-
ond, they observed more rapid heat inactivation of some mu-
tant proteins and suggested intracellular stability also may be
important. In this study, we have shown that mutant proteins
are rapidly polyubiquitinated and targeted for degradation via
the ubiquitin/26 S proteasome pathway. Moreover, degradation
correlates with the non-acetylated state of the allozyme. For
two of the alleles (NAT1*14 and NAT1*17), protein instability
also was demonstrated in PBMC from heterozygous individu-
als. From these studies, we propose the reaction model shown
in Fig. 7. NAT1 is acetylated in vivo to a stable form. Hydrol-
ysis of the acetyl-NAT1 is relatively slow but can be enhanced
by substrate that removes the acetyl moiety from the protein.
Mutant proteins that do not catalyze the formation of an acetyl
thiol ester exist in the non-acetylated state, which is ubiquiti-
nated and targeted for degradation. This model explains the
low protein levels seen with slow acetylator individuals and the
instability of mutant proteins reported here and elsewhere (7).
Moreover, it provides a plausible mechanism for the substrate-
specific down-regulation of NAT1 reported earlier (8) and con-
firmed in the present study.
The present observations are restricted to the specific slow
acetylator alleles studied (NAT1*14, NAT1*15, NAT1*17, and
NAT1*22). However, very low levels of translated protein were
also observed in yeast for NAT1*19 (7), suggesting that this
mutant protein also may undergo ubiquitination. There are
clear similarities between NAT1 instability and the NAT2 slow
acetylator phenotype described for some allelic variants. In
humans homozygous for NAT2*5A or NAT2*6A, there is a
decrease in immunodetectable protein present in the liver (20).
It will be important to determine whether NAT2 protein levels
in vivo can also be regulated by ubiquitination or down-regu-
lated by selective substrates.
NAT1 possesses a catalytic triad active site (14, 21). Struc-
turally, it is similar to many cysteine proteases such as the
caspases, transglutaminases, and deubiquitinases. The active
site is located within a cleft that may serve to exclude water
from the catalytic domain protecting the acetyl thiol ester at
Cys-68 from hydrolysis. Recently, Mushtaq et al. (22) showed
that the C-terminal sequence of NAT from Salmonella typhi-
murium controls hydrolysis of acetyl-CoA. Normally, the pro-
tein is stably acetylated, and therefore net hydrolysis of acetyl-
CoA is negligible. In the absence of the C terminus, the acetyl
protein is rapidly deacetylated and thus able to continually
catalyze the conversion of acetyl-CoA to coenzyme A. When the
C terminus was removed and expressed in bacteria, the result-
ing truncated NAT was toxic, possibly because of depletion of
intracellular acetyl-CoA. If a similar mechanism occurs in hu-
mans, then rapid degradation of non-acetylated protein may
be a protective mechanism against excessive hydrolysis of
acetyl-CoA.
The results from the present study indicated that the slow
acetylator phenotype is due to an inactive protein that is rap-
idly degraded within the cell, at least for NAT1 14, NAT1 15,
NAT1 17, and NAT1 22. They also demonstrated that substrate-
dependent down-regulation is due to rapid degradation of the
enzyme via the ubiquitin/26 S proteasome pathway. The dif-
ferent mutations in NAT1 that give rise to an inactive protein
change single amino acids located at different sites throughout
the enzyme. For NAT1 15, the mutation introduces a stop
codon and the protein is truncated at amino acid 186. The
common feature for each of the slow acetylator enzymes is their
inability to stably exist as an acetyl protein. The NAT1-C68Y
mutant confirmed the difference in stability of the acetylated
and non-acetylated proteins. Moreover, addition of substrate
(PABA), which would be expected to shift the equilibrium be-
tween acetylated and non-acetylated enzyme toward the non-
acetylated state, induced polyubiquitination and subsequent
protein degradation. These data suggest that acetylation of
Cys-68 may prevent access of ubiquitinases to target lysine
residues. Because NAT1 15 was ubiquitinated in a similar
manner as the other mutant proteins, the lysine residue(s)
most likely reside in the first 186 N-terminal amino acids. In
this region, there are seven lysines, two (Lys-13 and Lys-14)
are adjacent to a putative D-box (RXXL) that has been de-
scribed as necessary for the degradation of many cell cycle-de-
pendent proteins (23). However, preliminary mutagenesis of
FIG. 5. Stability of the NAT1C68Y mutant. A, binding of
[3H]acetyl-CoA to GSTNAT1 4 and GSTNAT1-C68Y expressed in bac-
teria. Conditions were as described in Fig. 4. Data are presented as
mean  S.E., n  3. * indicates significantly different (p 0.05) from
NAT1 4. B, Western blot analysis of His-NAT1 4 and His-NAT-C68Y
24 h after transient transfection of HT-29 cells and treatment with
cycloheximide (10 g/ml). Each band was quantified by densitometry
scanning and normalized to t  0 (C).
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these residues did not appear to affect ubiquitination.2 Further
mutagenesis work is underway to identify the crucial lysine(s)
involved in NAT1 degradation. Under conditions where sub-
strates are not present, NAT1 will exist in equilibrium between
an acetylated and non-acetylated state. From the reaction
mechanism (Fig. 7), the equilibrium is determined by the con-
centration of acetyl-CoA within the cell. The very long half-life
of NAT1 4 (24 h) suggests that the majority of the protein is2 A. Arulpragasam and N. Butcher, unpublished data.
FIG. 6. Ubiquitination of NAT1 proteins. A, effect of proteosomal inhibitor on the stability of NAT1 17. HT-29 cells were transfected with
FLAG-NAT1*17 and then treated concurrently with cycloheximide (10 g/ml) and MG132 (20 M) or vehicle (Me2SO). Cell lysates were prepared
at the indicated times and Western blots performed using anti-FLAG-M2 HRP antibody. In the absence of MG132, NAT1 17 showed rapid
degradation, whereas in the presence of the inhibitor it was stable over 8 h. B, formation of higher molecular mass products of the NAT1 allozymes
in the presence of MG132. HT-29 cells were transfected with FLAG-tagged NAT1 plasmids and then treated with MG132 () or vehicle (	) for 8 h.
Cell lysates were prepared and subjected to Western blot with anti-FLAG-M2 HRP antibody. The molecular mass of unmodified FLAG-NAT1 was
36 kDa except for the truncated NAT1 15, which was 26 kDa. C, formation of polyubiquitinated products of NAT1. HT-29 cells were co-transfected
with HA-ubiquitin plasmid and FLAG-tagged NAT1 plasmids. After 8 h of treatment with MG132, cell lysates were prepared and immunopre-
cipitated with anti-FLAG antibody, Western blotted, and probed with anti-HA antibody. Polyubiquitinated products are shown. D, effect of PABA
on polyubiquitination of NAT1 4. HT-29 cells co-transfected with HA-ubiquitin plasmid and FLAG-NAT1*4 were treated with MG132 or vehicle
for 8 h in the absence or presence of PABA (1 mM). Cell lysates were prepared and subjected to Western blot with either anti-FLAG-M2 HRP
antibody (left panel) or immunoprecipitated with anti-FLAG antibody and then subjected to Western blot with anti-HA antibody (right panel).
Polyubiquitinated products are shown.
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acetylated in vivo. A shift in equilibrium because of a change in
cofactor levels will lead to an increase or decrease in the
amount of NAT1 present in the cell. In this manner, NAT1 may
behave as a sensor of acetyl-CoA levels. However, further in-
vestigation is required to determine the relationship, if any,
between acetyl-CoA and NAT1 levels. Recently, Dupret and
co-workers (9, 10) have shown that oxidation of the active site
cysteine of NAT1 reversibly inhibits enzymatic activity. How-
ever, it is not known whether this modification affects protein
stability in vivo by altering the acetylation status of NAT1.
The differential stability of wild-type NAT1 and mutant
NAT1 proteins is similar to that observed for wild-type human
NAD(P)H:quinone oxidoreductase 1 (NQO1) and the mutant
protein NQO1 2. Anwar et al. (24) showed that the molecular
chaperone Hsp70, which catalyzes protein folding, associates
with the wild-type protein but not with the mutant protein
NQO1 2. It has been proposed that the amino acid change in
NQO1 2 disrupts the central parallel -sheet, resulting in a
decreased affinity for cofactor. Anwar et al. suggest that the
lack of association of Hsp70 with NQO1 2 may be because of its
inability to bind cofactor. It is plausible that a similar mecha-
nism exists for the mutant NAT1 proteins, where their inabil-
ity to bind the cofactor acetyl-CoA (demonstrated in the present
study) prevents their association with chaperone proteins such
as Hsp70 and leads to incomplete protein folding and subse-
quent ubiquitination and degradation. This also may explain
how mutations located throughout the NAT1 gene that change
single amino acids spatially distinct from the active site all lead
to the production of an inactive, rapidly degraded protein.
Further study is required to determine whether Hsp70 or any
other chaperone proteins interact with NAT1.
In summary, the present study provides experimental evi-
dence to support a molecular mechanism that may explain the
low level of protein expression from mutant NAT1 alleles. In
addition, it also may explain how substrates for NAT1 can
induce protein down-regulation and, therefore, modification of
NAT1 activity in vivo. The role of the ubiquitin/26 S protea-
some pathway in regulating NAT1 levels has not previously
been described for this or related protein families.
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FIG. 7. Model of the intracellular regulation of NAT1 by acetylation of cysteine 68. NAT1 undergoes acetylation on cysteine 68 to form
a stable thiol ester. Based on stability studies that show the deacetylation of NAT1 is a slow process (25), the equilibrium favors the formation of
acetyl-NAT1 in the absence of substrate. Deacetylation of NAT1 occurs when substrate is present, shifting the equilibrium to the non-acetylated
state. This form of NAT1 is rapidly ubiquitinated and degraded. Mutations that prevent acetylation (e.g. NAT1-C68Y) or result in a shift in the
equilibrium to the non-acetylated state produce an unstable protein that is rapidly degraded. The difference in stability of the acetylated and
non-acetylated protein accounts for the low NAT1 protein levels in heterozygous individuals as well as the substrate-dependent down-regulation
of NAT1.
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